510(k) device
Cobas Lithium
Roche Diagnostics Corp. · Assay, Porphyrin, Spectrophotometry, Lithium (NDW, Class II) · First FDA decision Mar 21, 2008, newest Mar 21, 2008Depression
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
19
Naming "Cobas"
MAUDE reports
27,616
Brand "Cobas", since 2015
PubMed studies
4,677
Mentioning "Cobas"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Cobas Lithium
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- COBAS LITHIUM510(k)
K063684 · Decided Mar 21, 2008 · 465 days after receipt
Device type: Assay, Porphyrin, Spectrophotometry, Lithium (NDW) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Cobas", any status and sponsor, newest update first.
- Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General PractitionerPivotal-lookingCompleted
University Hospital, LilleAcademic, hospital or other
NCT02749110 · 308 participants · Start Aug 28, 2016 · Primary completion Aug 23, 2019
Device: Vaginal self-sampling brush · For: Malignant Tumor of Cervix; Cervical Intraepithelial Neoplasia
Sites: Herzeele, France
- A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen TestPivotal-lookingRecruiting
bioLytical LaboratoriesNot on our public-company list
NCT07569900 · 650 participants (planned) · Start Nov 26, 2025 · Primary completion Dec 1, 2026
Device: iStatis Gonorrhea Antigen Test · For: Gonorrhea Infection
Sites: Johannesburg, South Africa; Durban, South Africa; Cape Town, South Africa
Foundation for Innovative New Diagnostics, SwitzerlandAcademic, hospital or other
NCT06213051 · 1,306 participants (planned) · Start May 16, 2024 · Primary completion Nov 18, 2024
Device: • COPAN Self-collection FLOQSwabs® (COPAN, Italy) · For: Human Papillomavirus Infection
Sites: Nairobi, Kenya
16 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Cobas", and for the whole product code for context.
This brand
27,616 reports: 27,470 malfunction, 131 injury, 7 death
Whole product code NDW
7 reports: 7 malfunction, 0 injury, 0 death
Newest reports for this brand
- cobas 6000 c501 moduleMalfunction
1823260-2026-04488 · Received Oct 29, 2026 · Event dated Oct 6, 2026
Device type: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (JJE)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- cobas 8000 cobas c 502 moduleMalfunction
1823260-2026-04491 · Received Oct 29, 2026 · Event dated Sep 1, 2026
Device type: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (JJE)
Device problem as coded: Non Reproducible Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- cobas c 503 analytical unitMalfunction
1823260-2026-04490 · Received Oct 29, 2026 · Event dated Oct 7, 2026
Device type: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (JJE)
Device problem as coded: Non Reproducible Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Cobas"[tiab]. The summary above synthesizes these.
- Profile of Roche's cobas® HCV tests.
Kessler HH, Stelzl E · Expert Rev Mol Diagn · 2017Review
- Clinical Performance of the cobas Liat SARS-CoV-2 & Influenza A/B Assay in Nasal Samples.
Akashi Y, Horie M, Kiyotaki J, et al. · Mol Diagn Ther · 2022Research Support, Non-U.S. Gov't
- Applicability of the cobas 6800 System for Epstein-Barr viral load quantitation using whole-blood specimens.
Song J, Kim S, Kwak E, et al. · Am J Clin Pathol · 2024
- Performance of the cobas EZH2 mutation test on clinical samples from non-Hodgkin lymphoma patients.
Shyu JY, Schlag PA, Karwowska SM, et al. · PLoS One · 2023
- Assessment of the cobas® HBV RNA investigational assay in the setting of nucleoside analog therapy cessation.
Jackson K, Bonanzinga S, Edwards R, et al. · J Med Virol · 2022Research Support, Non-U.S. Gov't
- Performance evaluation of the cobas SARS-CoV-2 Duo, a novel qualitative and quantitative assay, for the detection of SARS-CoV-2 RNA.
Su Y-D, Lai C-C, Lin T-H, et al. · Microbiol Spectr · 2023
- Possible False Results With cobas® EGFR Mutation Test v2 and Oncomine Dx Target Test for EGFR Mutation.
Kanaoka K, Tamiya A, Inagaki Y, et al. · Anticancer Res · 2023
- Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance.
de Vos M, David A, Duraisamy K, et al. · J Mol Diagn · 2024
- Evaluation of cobas Influenza A/B & RSV Test for Diagnosis of Equine Influenza.
Nemoto M, Okita N, Kitahata M, et al. · J Equine Vet Sci · 2020
- Performance evaluation of fully automated cobas® 6800 CMV PCR for the detection and quantification of cytomegalovirus DNA in neonatal urine and saliva, and adult urine, saliva, and vaginal secretion.
Tan NK, Pope CF, Carrington D · J Med Virol · 2023Research Support, Non-U.S. Gov't
- Diagnostic performance of the Cobas MTB and Logix Smart MTB for diagnosing pulmonary and extrapulmonary tuberculosis: a cross-sectional study of diagnostic tests.
Hueda-Zavaleta M, Gomez de la Torre JC, Minchón-Vizconde D, et al. · Ther Adv Infect Dis · 2024
- Validation of the cobas 6800 human papillomavirus test in primary cervical screening.
Sundström K, Lamin H, Dillner J · PLoS One · 2021Comparative Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code NDW.
- Diazyme Colorimetric Lithium AssayDiazyme Laboratories, Inc. · 510(k) 2025
- Dimension Vista Lithium Flex Reagent CartridgeSiemens Healthcare Diagnostics · 510(k) 2011
- Lithium Micro Volume ElectrodeThermo Electron OY · 510(k) 2007
- Sentinel Lithium AssaySENTINEL CH. SpA · 510(k) 2007
- Advia Ims Lithium AssayBayer Healthcare, LLC · 510(k) 2005
- Lithium Regent Model TR66056 / Lithium Standard TR66901Trace America, Inc. · 510(k) 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.